

This material is an English translation of the press release announced on September 20, 2019 in Japanese, and the Japanese release is given priority about the content and the interpretation.

September 20, 2019

**Notification of approval for manufacturing and marketing approval of
HARUROPI[®] TAPE in Japan
(Transdermal, Parkinson's disease treatment patch,
development code: HP-3000)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as "Hisamitsu Pharmaceutical") announces that it has obtained approval for manufacturing and marketing for HARUROPI[®] TAPE, transdermal, Parkinson's disease treatment patch (Development code: HP-3000, generic name: ropinirole hydrochloride, hereinafter referred to as "the product") in Japan as of today.

The product is a systemic transdermal formulation developed using Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. Hisamitsu Pharmaceutical expects its long-lasting effect by means of maintaining a stable blood concentration, and the product to be a new option for treating Parkinson's disease.

Kyowa Kirin Co., Ltd., (Head office: Chiyoda-ku, Tokyo, Japan; President: Masashi Miyamoto, hereinafter referred to as "Kyowa Kirin") that have entered an agreement for exclusive rights to commercialize the product in Japan in February 2019, will be responsible for commercializing the product.

In addition, Hisamitsu Pharmaceutical will receive milestone payments based on the regulatory approval.

Hisamitsu Pharmaceutical and Kyowa Kirin will contribute to further improving the quality of life of patients who suffer from Parkinson's disease by providing proper medical information of the product.

Reference:

Trade name	HARUROPI® TAPE 8 mg HARUROPI® TAPE 16 mg HARUROPI® TAPE 24 mg HARUROPI® TAPE 32 mg HARUROPI® TAPE 40 mg
Active pharmaceutical ingredient	Ropinirole hydrochloride
Indication	Parkinson's disease
Dosage and Administration	Usually, for adults initially apply 8mg formulation as Ropinirole hydrochloride once daily, observing the progress, increased as needed the daily dose by 8 mg at intervals of 1 week or more. For any dose, apply once daily to the skin of the chest, abdomen, flank, thigh or upper arm and replace every 24 hours. Further, the dosage can be adjusted according to the age and the symptoms, the daily dosage should not exceed 64mg as Ropinirole hydrochloride.
Size of formulation	5.33 cm ² (HARUROPI® TAPE 8 mg) 10.67 cm ² (HARUROPI® TAPE 16 mg) 16.00 cm ² (HARUROPI® TAPE 24 mg) 21.33 cm ² (HARUROPI® TAPE 32 mg) 26.67 cm ² (HARUROPI® TAPE 40 mg)